摘要
目的观察急性冠脉综合征(ACS)患者使用大剂量阿托伐他汀联合替罗非班对血浆超敏C反应蛋白(hsCRP)及颈动脉粥样硬化的影响。方法对126例ACS患者随机分三组,A组30例,每晚服用20mg阿托伐他汀;B组41例,每晚服用阿托伐他汀40mg;C组55例,采用每晚服用阿托伐他汀40mg,联合24,48h替罗非班。随访6个月,观察血浆hsCRP、彩色多普勒技术测定颈动脉内一中膜厚度(IMT)变化。结果三组治疗12个月,均能显著降低hsCRP,且三组比较差异有显著性;B、C两组能降低双侧IMT,且两组之间有显著性差异。结论ACS应用大剂量阿托伐他汀联合替罗非班治疗,明显抑制hsCRP,减少颈动脉粥样硬化,降低心脏事件发生。
Objective To study effects of high dosage of atorvastatin in acute coronary syndrome(ACS) patients on high sensitive creactive protein(hsCRP) and atherosclerosis. Methods 126 cases with ACS were divided into A, B and C group. 30 patients in A group were given atorvastatin 20mg per night,41 cases in B group were given atorvastatin 40mg per night, while the other 55 patients in C group were taken atorvastatin 40mg per night and tirofiban in the first 24 to 48 hours. The patients were followed 6 months by evaluating serum hsCRP concentration, measuring the intimal thickness in the carotid artery with color Doppler. Results After treatment for 6 months, the patients in the three groups showed significant decrease in hsCRP, however, the therapeutic group showed significant difference amony the three groups. Additionally, the B and C groups further showed significant decrease in intimal thickness. Conclusion Using high-dose atorvastatin and tirofiban not only lowers hsCRP significantly,but also benefit stability of atherosclerotic plaque in carotid artery, and to reduce cardiovascular events.
出处
《中国基层医药》
CAS
2012年第5期703-705,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
阿托伐他汀
急性冠脉综合征
超敏C反应蛋白
颈动脉硬化
Atorvastatin
Acute coronary syndrome
High sensitive C-reactive protein
Carotid atherosclerosis